Advisor Group Holdings, Inc. Atai Life Sciences N.V. Transaction History

Advisor Group Holdings, Inc.

$42.2 Billion
Q3 2024

A detailed history of Advisor Group Holdings, Inc. transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 3,632 shares of ATAI stock, worth $5,520. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,632

Previous 3,637 0.14%

Holding current value

$5,520

Previous $4,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$1.16 - $1.64 $5 - $8	-5 Reduced 0.14%	3,632 $4,000
Q2 2024 Aug 13, 2024	BUY	$1.27 - $2.6 $2,978 - $6,097	2,345 Added 181.5%	3,637 $4,000
Q1 2024 May 10, 2024	SELL	$1.5 - $2.19 $240 - $350	-160 Reduced 11.02%	1,292 $2,000
Q4 2023 Feb 12, 2024	SELL	$1.04 - $1.55 $927 - $1,382	-892 Reduced 38.05%	1,452 $2,000
Q3 2023 Nov 13, 2023	BUY	$1.27 - $2.28 $1,132 - $2,033	892 Added 61.43%	2,344 $3,000
Q2 2023 Aug 10, 2023	SELL	$1.44 - $2.19 $2,880 - $4,380	-2,000 Reduced 57.94%	1,452 $2,000
Q1 2023 May 12, 2023	BUY	$1.17 - $2.7 $393 - $907	336 Added 10.78%	3,452 $6,000
Q3 2022 Nov 14, 2022	BUY	$3.14 - $4.87 $2,800 - $4,344	892 Added 40.11%	3,116 $11,000
Q2 2022 Aug 10, 2022	BUY	$3.03 - $5.32 $3,635 - $6,384	1,200 Added 117.19%	2,224 $8,000
Q1 2022 May 04, 2022	SELL	$4.66 - $7.66 $42,131 - $69,254	-9,041 Reduced 89.83%	1,024 $5,000
Q3 2021 Nov 05, 2021	BUY	$13.62 - $19.48 $111,207 - $159,054	8,165 Added 429.74%	10,065 $149,000
Q2 2021 Aug 02, 2021	BUY	$16.94 - $19.89 $32,186 - $37,791	1,900 New	1,900 $36,000

Others Institutions Holding ATAI

# of Institutions

Shares Held

12.4M

Call Options Held

77.8K

Put Options Held

50.3K

View Full List

About ATAI Life Sciences N.V.

Ticker ATAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 165,875,008
Market Cap $252M
Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...

More about ATAI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.

Account

Advisor Group Holdings, Inc. Atai Life Sciences N.V. Transaction History